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The serological analysis of human  B  cell alloantigens has led to the definition of a 
HLA-linked locus, designated HLA-DR  (1,  2),  which  codes for human  Ia antigens, 
i.e., human homologues ofmurine Ia antigens. Thus far, 10 allospecificities have been 
assigned to this locus. 
Evidence has been  accumulating over the past few years that  human  Ia antigens 
are controlled by at least two HLA-linked loci. The first indication was the discovery 
of a  subset of Ia molecules carrying a  non-DR  specificity DC1  by immunochemical 
analysis at  the molecular level  (3). This determinant  is controlled by an  allele at  a 
separate locus in  strong linkage disequilibrium with  three  alleles of the  DR  locus, 
DR1, DR2, and DRw6  (4, 5). Structural characterization by microfingerprinting (6) 
and by two-dimensional electrophoresis (7) has shown that DC 1 molecules differ from 
DR molecules. This identification of a second Ia locus has unveiled a  basic homology 
of the human Ia system with the murine system in which two subsets of Ia molecules, 
I-A and I-E, exist (8). 
The elucidation of another Ia specificity, BR4X7  (9)  or HON7  (10), has revealed 
an additional complexity of the human  Ia system. This specificity is controlled also 
by an  HLA-linked locus different  from  the  DR  locus  and  is transmitted  in  strong 
linkage  disequilibrium  with  the  DR4,  DR7,  and  DRw9  alleles  (5).  BR4X7  could 
conceivably be allelic to DC 1 and thus be incorporated in a  two-loci model. However, 
peptide mapping analysis showed that the molecules carrying BR4X7 specificity are 
far more similar to DR molecules than to DC1  molecules,  1 leading to the assumption 
that DC1  and BR4X7 may not be allelic. Consequently, a  third HLA-linked Ia locus 
would be required to accommodate BR4X7. 
Direct evidence for or against a  three-loci hypothesis cannot be obtained using the 
specificities DC1  and BR4X7  because they are always transmitted in repulsion as a 
result  of their  association  with  nonoverlapping  sets  of DR  alleles.  More  complete 
immunochemical  testing  of  the  three-loci  concept  requires  the  consideration  of 
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additional specificities. Such specificities can be found  in  the supertypic specificities 
of two  HLA-DR-associated systems  designated  MB  (11)  and  MT  (12).  Three  MB 
specificities have been recognized; each shows a  strong association with two or more 
DR specificities: MB1  with DR1,  DR2, and DRw6;  MB2 with DR3  and DR7;  and 
MB3  with  DR4,  DR5,  DRw6,  and  DRw9.  The  MT  specificities  are,  with  the 
exception of MT1,  associated with other groups of DR specificities: MT1  with DR1, 
DR2,  and DRw6;  MT2 with DR3,  DR5,  DRw6,  and  DRw8;  and  MT3  with DR4, 
DR7, and DRw9. The DC1 is equivalent to MB1 and MT1, and the BR4X7 is similar 
and probably identical to MT3. 
In this study, the MB2 specificity that  frequently forms an HLA haplotype along 
with  DR7  and  BR4X7  was  analyzed  at  the  molecular  level  by  using  an  HLA- 
homozygous cell line expressing these three specificities. We have found that the DR7, 
BR4X7,  and MB2 determinants correspond to three distinct molecular subsets with 
different structural features as well as with a  different population distribution. These 
data substantiate the three-loci concept for the genetic control of human Ia antigens. 
Materials and  Methods 
Antisera.  Most of the alloantisera used were derived from Ferrara and Duquesnoy serum 
panels. Some were kindly provided by other laboratories: serum  HON  by Dr.  M.  Katagiri, 
Asahikawa Medical College, Asahikawa, Japan; serum T-1514 by Dr. T. Juji, Tokyo University 
School of Medicine, Tokyo; serum 8-4513 by Dr. K. Tsuji, Tokai University School of Medicine, 
Isehara, Japan. Serum KIT 13390 is an Eighth Histocompatibility  Workshop antiserum, 8W455, 
that  was  provided  by  Dr.  K.  Gelsthorpe,  National  Blood  Transfusion  Service,  Sheffield, 
England.  Sera Murphy  and  Gallardo were obtained  from  the serum  bank  of the  National 
Institute of Allergy and Infectious Diseases, Research Resources Branch, Bethesda, MD (NIH). 
Some of the antisera used were studied during the Eighth Histocompatibility Workshop and 
their specificity was assessed by cytotoxicity assay. These antisera were tested for their binding 
properties by  radioimmunoassay using  a  panel  of 12Sl-labeled  Ia  preparations  of different 
phenotypes. In general, a good correspondence was found between the specificities detected by 
cytotoxicity and by molecular binding (13). The specificity of other alloantisera was defined by 
radioimmunoassay only. In several cases the definition of specificity was facilitated by typing 
the immunizer (father, or volunteer blood donor in cases of planned immunization) and the 
antibody producer (mother, or volunteer blood recipient in cases of planned immunization). 
Table I lists the alloantisera used, their known specificities, and other available data. 
In addition, two rabbit antisera, anti-human Ia antiserum 7147 and anti-human Ia a-subunit 
antiserum  Ul15,  were  used.  The  former  was  raised against  a  preparation  of Ia  molecules 
purified from  Daudi cells and  its specificity has been  fully assessed  (9,  14). The  latter was 
generated against an a-chain preparation isolated by sodium dodecyl sulfate (SDS)-polyacryl- 
amide  gel  electrophoresis from  a  pooled  Ia  preparation  that  was  derived  from  peripheral 
leukocytes of five patients with chronic lymphocytic leukemia. Aliquots corresponding to ~0.02 
A2s0 units were injected intramuscularly at weekly intervals with complete Freund's adjuvant. 
The antiserum obtained after 2 mo reacted only with isolated Ia c~-chains and not with Ia/8- 
chains. The antiserum also bound intact Ia molecules irrespective of their DR specificity. This 
binding was inhibited only by Ia a-chains and not by Ia fl-chains. Moreover, the antiserum was 
found  to bind only DR  and  BR4X7  molecules and  not  to bind DC1  molecules. In fact, by 
starting with  a  Daudi  Ia preparation  containing ~70%  DRw6  molecules and  <I0%  DC1 
molecules and  depleting the preparation of DRw6  molecules specifically by the use of this 
antiserum, a preparation was obtained in which these proportions were approximately reversed 
(15). 
Antigen Preparation.  The Ia preparation that  was analyzed was purified by the procedure 
described in detail (16) from a HLA-Dw7 homozygous cell line, LG-10, established by Dr. W. 
Leibold, Institute for Pathology, Hannover, Federal Republic of Germany. This cell line had 
been typed to be DR7-positive and BR4X7-positive by radioimmunoassay (5,  17). TANIGAKI, TOSI, DUQUESNOY,  AND  FERRARA  233 
TABLE  I 
Alloantisera Used  in the Present Study 
Incompatible  Detected 
Antiserum  Laboratory  specificity*  specificity:~ 
Fe96/19  Ferrara  DR1, DR3, DC1, MB2  DC1, MB2 
Fe59/15  Ferrara  DR4, BR4X7  DR4, BR4X7 
Fe27/26  Ferrara  DR7, BR4X7, MB2  DR7, BR4X7, MB2 
Fe53/23  Ferrara  DR7, BR4X7, DC1  DR7, BR4X7, DC1 
Fe 118/13  Ferrara  DR7, MB2  DR7, MB2 
Duffy  Duquesnoy  DR3, MB2  DR3, MB2 
Tellier  Duquesnoy  DR3, MB2  DR3, MB2 
Swift  Duquesnoy  Not available  DR4, BR4X7 
Eckert  Duquesnoy  Not available  DR7, BR4X7, MB2 
Gnadt  Duquesnoy  DR7, BR4X7, MB2  DR7, BR4X7 
Keliher  Duquesnoy  Not available  DR7, BR4X7 
HON  Katagiri  Not available  BR4X7 
T- 1514  Juji  Not available  DR4, BR4X7 
8-4513  Tsuji  Not available  DR4, BR4X7 
KIT13390  Gelsthorpe  Not available  DR4, BR4X7 
Murphy  NIH§  Not available  DR4, BR4X7 
Gallardo  NIH  Not available  DR4, BR4X7 
* Incompatibilities were established  by cytotoxicity  typing of immunizer and serum 
producer.  DC1 is equivalent to MB1 or MT1 and BR4X7 to HON7 or MT3. 
:[: The specificities were assessed by cytotoxicity assay and/or radioimmunoassay. 
§ National Institutes of Health. 
Briefly, crude cell membranes were isolated by differential centrifugation from ~13 g  (wet 
weight)  of packed  LG-10 cells  (~6.5  ×  109 cells)  disrupted by nitrogen decompression and 
solubilized with 2% Renex 30 (Ruger Chemical Co., Irvington, N  J). The solubilized material 
was separated by uhracentrifugation and subjected to affinity chromatography on a column of 
lentil lectin-coupled Sepharose (18).  The retarded fraction was concentrated by uhrafiltration 
and  fractionated  by  gel  filtration on  a  column of Bio-Gel  A1.5M  (Bio-Rad  Laboratories, 
Richmond,  CA;  bed  vol:  100  ml).  The  major  fractions  with  high  human  Ia  activity  as 
determined by the binding inhibition assay (19) were pooled. The yield was 3.84 as determined 
by absorbance at 280 nm. 
A small amount (0.020 A280 units) of the pool was trace-labeled with x~sI by the ehloramine 
T  method (20). The labeled preparation (~50 mCi/A280 unit) was fractionated on a column of 
Bio-Gel A1.5M (bed vol 50 ml), and the major fractions which gave high binding with rabbit 
anti-human Ia antiserum as determined by the direct binding assay (21) were pooled. Binding 
with rabbit anti-human Ia antiserum was 63%. This preparation was used mostly for sequential 
binding experiments and peptide analyses. 
To obtain a preparation depleted of DR7 and BR4X7 molecules, a small amount (0.040 A280 
units in 40-#1 vol) of the  LG-10 Ia preparation was absorbed before radiolabeling, with the 
Sepharose-bound antiserum U 115 (200 pl of a 33% suspension of Sepharose-4B coupled with 10 
mg crude immunoglobulins/ml  gel) at 4°C for 24 h on a rotating wheel and then radioiodinated. 
The labeled preparation was subjected to papain digestion at 37°C for 30 min using an enzyme 
to substrate ratio of 1:40 (10 mg bovine serum albumin as carrier) at pH 7.8 in the presence of 
10  mM  cysteine-HCt  and  1  mM  EDTA.  The  digestion  was  terminated  by  addition  of 
iodoacetamide in slight molar excess over eysteine. The digest  was further processed  by gel 
filtration on Bio-Gel A 1.5M followed by lentil lectin affinity chromatography, a procedure that 
separates the intact from  the papain-sp]it Ia molecules and improves the purity of the  final 
products, as previously described in detail (15,  16, 21). The papain-split, DR- and BR-depleted 
Ia preparation showed a  purity of 85%.  It was used as the reference labeled antigen for the 
radioimmunoassay of MB2 specificity. 
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typing of DR specificities and  for DC1  and  BR4X7  typing was  followed  (5,  16,  17).  Briefly, 
leukocytes obtained  from  defibrinated  blood were lysed with  Renex  30.  A  portion  of lysate 
corresponding  to  7  ×  10  a  cells  was  added  to  2  /~l  of  reference  antiserum  Fe96/19.  After 
incubation  for  16  h  at  room  temperature,  ~10,000  cpm  of the  labeled  Ull5-treated  LG-10 
preparation,  prepared as above, was added.  After a  further  16-h incubation at room tempera- 
ture,  the  immune  complexes  were  precipitated  by  a  goat  anti-human  Ig  antiserum.  The 
precipitate obtained was washed and the radioactivity was determined. The extent of inhibition 
was calculated as the percentage of the radioactivity precipitated in the absence of inhibitor. 
For typing cell lines, the same procedure was adopted, except that 5 I11 of a 20% (vol/vol) cell 
lysate was used and the incubation time for alloantibody with inhibitor was reduced to 4 h  at 
room  temperature.  Typing of cell lines was also  performed  using an  LG-10  preparation  not 
treated with U115. The percentage of Ia molecules carrying MB2 specificity was low (~ 10% vs. 
>40% in the enriched preparation)  but still sufficient to clearly distinguish between inhibitors 
and noninhibitors. An assay was also performed under these conditions using antiserum  Dully 
(5 p,l) instead of Fe96/19. 
Direct-binding Assay and Sequential-binding Assay.  The direct-binding assay used for measuring 
the  binding  activity  of alloantisera  was  carried  out  as  previously  described  in  detail  (16). 
Briefly,  equal  portions  of  an  125Idabeled  Ia  preparation  having  10,000-20,000  cpm  were 
incubated  with  5  ~l  of test  alloantisera  in  a  total  reaction  vol  of 60  #1  for  16  h  at  room 
temperature and further with an optimum amount of goat anti-human Ig antiserum  for 1 h at 
room temperature.  The resultant  immune  precipitate was  washed  and  the radioactivity was 
determined.  A  control  with  normal  human  serum  was  included  in  each  assay.  Results  were 
expressed as the percent Ia binding, which indicates the proportion of the maximum binding 
obtained with rabbit  anti-human Ia antiserum  7147. 
The sequential-binding assay used to determine the relationship between Ia molecules bound 
by  alloantisera  of different  Ia  specificities  was  also  performed  as  described  previously  (9). 
Briefly,  the  first  binding  reaction  was  carried  out  by  incubating  an  12SI-labeled  LG-10  Ia 
preparation with a selected human Ia alloantiserum for 4 h at room temperature. After further 
incubation  with  goat  anti-human  Ig  antiserum  for  1 h  at  room  temperature,  the  resultant 
precipitate was removed by centrifugation.  The supernatant  was subsequently assayed by the 
direct-binding  assay  for the remaining binding  activity with  a  set  of human  Ia  alloantisera, 
including the antiserum used in the first binding reaction. The extent of binding in the second 
binding  reaction  was  expressed  as  the  percentage  of the  control  binding,  i.e.,  the  extent  of 
binding given by the labeled Ia preparation treated with normal human serum under the same 
conditions. 
Microfingerprinting.  The  125I-labeled  Ia  molecules  bound  by  a  given  alloantiserum  were 
recovered on protein A-coupled Sepharose (Enzyme Center, Boston, MA) using 300/LI of a 20% 
suspension  for 50 ~1 of alloantiserum  and  eluted  with 0.5  ml of a  1%  SI)S  solution.  The  Ia 
subunits  were separated  by  polyacrylamide  gel electrophoresis  on  a  10%  gel  (10  X  90  ram) 
containing  0.1%  SDS  according  to  the  method  described  by  Laemmli  (22).  The  separated 
subunits were eluted from the segmented gels by overnight  incubation at 4°C with Tris-HC1 
buffer (Tris 0.037  M, pH 7.8)  containing 0.05% SDS. 
The  peptide  analysis  of isolated subunits  was  performed  by a  two-dimensional  mapping, 
which has a  higher resolving power than  one-dimensional analysis  (6),  using a  slight modifi- 
cation  of  the  method  originally  described  by  Mole  (23).  The  subunit  preparations  were 
concentrated  to <0.5 ml by Speed Vac, a  concentrator  (Savant  Instruments,  Inc., Hicksville, 
NY), reduced, and alkylated in the presence of 50/xg rabbit  IgG and precipitated with an acid 
mixture  at  a  finat  concentration  of 10%  trichloroacetic acid and  4% sulfosalicytic acid.  The 
precipitates were washed with acetone and then with methanol, dissolved with  100 ~l of 0.1M 
ammonium carbonate, and digested with elastase at 37°C overnight using an enzyme to protein 
ratio of 1:20.  The digest was dried by the Speed Vac, dissolved with a small volume of a  thin- 
layer electrophoresis buffer (water/acetic acid/pyridine  189:10:1)  and subjected to electropho- 
resis on a  silica gel plate, Silica Gel 60  (E.  Merck, Darmstadt,  Federal Republic of Germany) 
followed by thin-layer chromatography as described by Feinstein et al. (24).  The map obtained 
was  autoradiographed  on  a  Kodak  x-ray  film,  X-Omat  AR,  using  the  regular  intensifying 
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Results 
The  Presence  of  Molecules Reacting with  Anti-MB2  Antisera  in  the  LG-IO  Ia 
Preparation.  HLA-Dw7  homozygous LG-10 cells,  besides  being DR7-positive, were 
also  positive  for  BR4X7,  a  specificity associated  with  DR4,  DR7,  and  DRw9,  as 
determined  by  the  radioimmunoassay  (5).  These  two  specificities  have  previously 
been shown  to be carried  on  different  Ia molecules  (9),  and  thus  if the human  Ia 
system is controlled by three loci, the LG-10 cells would be expected to express a third 
Ia subset carrying another distinct  alloantigenic specificity. The best candidate as a 
marker of this third component was the MB2 supertypic specificity, also called Te24 
(25),  that was known  to be associated with  DR3 and DR7  at  the population  level 
from cytotoxicity studies  (121).  Therefore, a  lZSI-labeled Ia preparation from LG-10 
cells  was  tested  with  other  labeled  Ia  preparations  of various  DR  phenotypes  for 
reactivity with  a  series of relevant  antisera,  including  those  known  or supposed  to 
possess anti-MB2 activity. 
The binding data for LG-10 and two other Ia preparations are shown in Table II 
for the pertinent antisera. The LG-10 Ia preparation gave high binding levels in the 
reaction with antisera possessing anti-MB2 activity, which were raised against DR7- 
positive immunizers, e.g.,  Fe27/26  or Fe118/I3,  indicating  that  they contain  anti- 
DR7 antibodies as well. Just as DR molecules are the dominant species of Ia molecules 
accounting for 70-80% of the total Ia pool, so are DR7 molecules in LG-10 cells; thus 
these antisera could hardly be used to reveal the minor Ia component carrying MB2 
specificity unless the anti-DR7 antibodies are depleted. Only the anti-MB2 antisera 
raised against a DR7-negative, DR3-positive immunizer were expected to give mean- 
TABLE  II 
Binding Properties of a251-labeled LG-IO Ia Preparation with Alloantisera 
Antiserum 
Extent of binding of 125I-labeled 
Ia preparation* 
LG- 10  Chevalier  U698M 
(DR7, DR7)  (DR3, DR7)  (DR2, DR4) 
Fe96/19  13.0  16.5  15.3 
Duffy  6.6  7.8  1.4 
Tellier  7.2  7.3  1.6 
Fe53/23  66.0  40.2  10.0 
Fe27/26  73.7  49.3  13.4 
Fe118/13  52.3  31.6  1.0 
Eckert  79.5  48.7  11.2 
Gnadt  61.7  40.5  8.4 
Keliher  66.5  48.0  13.9 
HON  8.7  11.0  11.3 
Fe59/15  7.7  13.3  28.6 
Swift  9.4  11.9  49.9 
T-1514  9.1  14.9  41.8 
8-4513  7.2  13.4  49.0 
KIT 13390  7.2  9.8  43.5 
Murphy  6.3  10.4  44.2 
Gallardo  7.1  14.2  40.5 
* The extent of binding was determined using 5 pl 
binding assay and is  presented as the percent Ia 
Methods). 
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ingful results. Among the antisera fitting these conditions, Fe96/19, Duffy, and Tellier 
were found to give a  reasonably low, at most  13%,  but still significant  binding level. 
It should be pointed out that the producer of serum Duffy was DR7 +, MB2-, MT3-, 
whereas  the  immunizer  was  DR3 +,  MB2 +,  MT2 ÷.  Anti-DR4  antisera  also  showed 
low binding,  ~8%, similar to that of antiserum  HON. This binding has been shown 
to be due to reaction with the BR4X7 subset  (9,  10). 
The  binding  characteristics  of LG-10  Ia  preparation  with  three  representative 
alloantisera,  Fe53/23  (anti-DR7,  BR4X7),  HON  (anti-BR4X7),  and  Fe96/19  (anti- 
MB2), are depicted in Fig.  1. A clear binding plateau which indicates the presence of 
an Ia subset can be seen at a  level of ~9% in reaction of the untreated  Ia preparation 
with  serum  HON  (Fig.  1 A).  This  subset  corresponds  to  the  BR4X7  identified 
previously in the Ia preparations purified from two DR-heterozygous cell lines, one of 
DR3 and DR7 and another of DR2 and DR4  (9).  The deletion of BR4X7 subset  by 
treatment  with  the  serum  HON  induced  little  change  in  the  binding pattern  with 
either of Fe53/23  and Fe96/19  (Fig.  1 B). The binding level with these two sera was 
substantially reduced by absorption with serum Fe118/13 of DR7 and MB2 specific- 
ities (Fig.  1 C). The same procedure produced a marked elevation of the binding level 
with  serum  HON:  the plateau  formation is  now seen  at  a  level of ~30%  (Fig.  1 C). 
This selective elimination or enhancement of the reactivity with serum HON indicates 
that  the BR4X7 determinant  recognized by serum  HON  is carried  by a  subset  that 
is immunospecifically separable from those reacting with Fe53/23 or Fe96/19. 
A  similar increase of the binding level with Fe96/19 was attained  by a  procedure 
that  was  proven effective in  increasing  the  proportion  of Ia molecules  carrying the 
DC 1 determinant  in a  Daudi  (DRw6, DC 1) Ia preparation.  This procedure involves 
two steps: a depletion of DR and BR molecules by the use of rabbit antiserum  U 115 
specific to the a-chains of DR and BR molecules and a limited digestion with papain 
(Materials  and  Methods).  As shown in Table III, the same procedure was found to 
considerably  increase  the  proportion  of Ia  molecules  reacting  with  the  Fe96/19 
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F,c.  1.  The binding characteristics of LG-10 Ia preparation with three representative alloantisera. 
]2~I-labeled LG-10 Ia preparation (520,000 cpm), (A) untreated, or (B) treated with antiserum HON 
(anti-BR4X7; 0.5/*1), or (C) treated with antiserum Fe118/13 (anti-DR7, MB2; 25 p.l), was tested 
for binding activity with varying amounts of antisera Fe53/23 (anti-DR7, BR4X7), HON (anti- 
BR4X7), and Fe96/19 (anti-MB2) by the direct-binding assay. The binding activity was expressed 
as the percent Ia binding and plotted against the amount  of antiserum used. The antisera used 
contain antibodies not reacting with LG-10 Ia preparation as specified in Table I; only the relevant 
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TABLE III 
Enrichment* of Ia Molecules that React with Anti-MB2 Antisera 
Antiserum  Relevant specificity§ 
Extent of binding of 
LG- 10 Ia preparation:]: 
Untreated 
Treated with 
anti-la a sub- 
unit 
Fe96/19  MB  2  12.9  4 l. 1 
Fe53/23  DR7, BR4X7  68.2  17.7 
KIT 13390  BR4X7  7.2  7.4 
Fe27/26  DR7, BR4X7, MB2  80.8  67.0 
* MB2  molecules were enriched  by a  selective depletion  of DR  and  BR 
molecules by the use of rabbit antiserum Ut I5 specific to the a-chains of DR 
and BR molecules and a limited papain digestion (Materials and Methods). 
The extent of binding was determined using 5/tl antiserum by the direct 
binding assay and is presented as the percent Ia binding  (Materials and 
Methods). 
§These antisera contain  additional  antibodies  not  reacting with  LG-10 Ia 
preparation as specified in Table I. 
antiserum  in  the  LG-10 Ia preparation.  Binding  with  Fe53/23  produced  against  a 
DR7-positive,  MB2-negative  immunizer  was  reduced,  whereas  BR4X7  reactivity 
remained  low.  This selective  increment  of the binding level with  Fe96/19  indicates 
that  the  alloantigenic  specificity  recognized  by  anti-MB2  antisera  and  the  DC1 
specificity may well be allelic. 
Immunogenetic Analysis  of the  MB2  Specificity by  the Radioimmunoassay.  It  was  then 
determined  if the  determinant  recognized  by  anti-MB2  antisera  in  the  preceding 
experiments  corresponds  to  the  supertypic  specificity  MB2  defined  by cytotoxicity 
with respect to population distribution,  association with DR allelic specificities,  and 
segregation  in  families.  The  results  indicated  that  this  specificity  defined  by  the 
molecular binding conforms in all these aspects to the MB2 specificity. 
Individuals can be typed for an Ia allospecificity by testing their peripheral  blood 
leukocytes for inhibitory activity on the binding of a  125I-labeled Ia preparation by a 
specific alloantiserum  (17).  For the present  MB2  typing by the  radioimmunoassay, 
the  Ull5-treated  LG-10  Ia preparation  described  above was  used  as  the  reference 
antigen  in combination  with  Fe96/19,  which was found to possess  the highest  titer 
among the  available  anti-MB2  antisera.  As shown  in  Fig.  2,  121  specimens  from a 
panel of HLA-typed individuals  and families were unequivocally distributed  in two 
groups,  an  MB2-positive  group  and  an  MB2-negative  group.  In  accord  with  the 
association  pattern  of MB2  specificity  by  the  cytotoxicity assay,  the  positive  cells 
included exclusively DR3-positive and/or DR7-positive cells.  Within  this group, the 
two phenotypes did not appear to be associated with different degree of inhibition. A 
substantial  proportion of DR3-positive or DR7-positive individuals were found to be 
in  the  negative  group.  These  relationships  among  MB2,  DR3,  and  DR7  at  the 
population level is more clearly illustrated  by Fig.  3, which includes  only unrelated 
individuals  positive  for these  three  specificities.  37%  of DR3-positive  individuals  (7 
out of 19)  and also 37% of DR7-positive individuals  (10 out of 27), excluding DR3, 
DR7 heterozygotes from the calculation, were MB2-negative.  These proportions are 
similar to those found by cytotoxicity for the Te24 specificity in its relationship  with 238  GENETIC  CONTROL  OF  HUMAN  Ia  ANTIGENS 
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Fro.  2.  MB2 typing by the radioimmune inhibition assay of a  panel of HLA-typed individuals 
and family members. The assay was performed by using the U115-treated,  ~2Sl-labeled  LG-10 Ia 
preparation as the reference antigen in combination with Fe96/19  (Materials and Methods). Each 
box represents an individual and is collaborated in the diagram according to the extent of inhibition 
in the performed assay. The numeral within box indicates the presence of DR3 and/or DR7. The 
total number of individuals typed was 121. 
DR3 and DR7 (25).  Some DR7-positive individuals have been known to be negative 
for the BR4X7 specifity, which is tightly associated with DR4 and DR7 (5, 9). Three 
such cases, cell donors 644, 539, and MF83, found in the present panel all turned out 
to be also MB2-negative, suggesting a  linkage  disequilibrium  condition  specifically 
involving the MB2 and BR4X7 specificities. 
30  B  cell-type  cell  lines  available  from  the  Roswell  Park  Memorial  Institute, 
Buffalo, NY were also typed. The results (Fig. 4) are similar to those obtained in the 
normal population. The MB2 specificity was tightly associated with DR3 and DR7. 
Also in these cell lines, two DR3-positive cells, RPMI 8392  and 6410, were found to 
be negative for MB2 and the two DR7-positive, BR4X7-negative cases, RPMI 5287 
and 8068, both turned out to be MB2-negative. 
The  inhibition  assay  of cell  lines  was  repeated  using  an  12SI-labeled  LG-10  Ia 
preparation,  unprocessed  for the  enrichment  of MB2,  in  combination  with  either 
antiserum Fe96/19  or Duffy. The same qualitative results were obtained, suggesting 
the similarity of the  determinants  recognized by these  two  antisera and  indicating 
that the enrichment procedure involving papain digestion did not affect the alloan- 
tigenic specificity of Ia molecules (data not shown). 
The members of 13 families that were extensively typed during the Eighth Histo- 
compatibility Workshop were also tested. Three families showed segregation of MB2, 
transmitted in coupling with DR7 in one case and with DR3 in the other two cases 
(Table  IV).  Notably,  the  family 8wFER01  shows  segregation  of all  three  non-DR 
markers:  DC1, BR4X7,  and MB2.  No instance  of crossing over between  MB2  and 
any of the other HLA markers was found in any family studied. 
Sequential Binding Experiments.  The three specificities DR7, BR4X7, and MB2 have 
different  population  patterns,  but  this  does  not  necessarily mean  that  they  are  all 
carried by distinct  sets of Ia molecules, although the selective enrichment of BR4X7 
molecules (Fig.  1) and of MB2 molecules (Table II) provided evidence suggesting this Coil 
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FIG.  3.  Schematic representation of the MB2-DR3-DR7  relationship. The figure includes only 
individuals positive for these three specificities. Only panel members and unrelated parents have 
been included. The total number of individuals typed was  101. Positivities are indicated by dots. 
Frames are drawn to clarify the relationships between the three specificities. DC 1, MB2, and BR4X7 
typing was performed by radioimmunoassay. DR typing was done by cytotoxicity assay with Eighth 
Histocompatibility Workshop antisera and confirmed in most cases by radioimmunoassay. 
possibility. A direct proof was provided by sequential-binding experiments using the 
antisera corresponding to the three specificities. The 12~I-labeled LG-10 Ia preparation 
was first allowed to react with  the HON antiserum, which possesses  a  strong anti- 
BR4X7  reactivity.  After  removing the  immune  complexes by  reaction  with  anti- 
human Ig antiserum, the supernatant was tested with three groups of antisera that 
possess anti-BR4X7, anti-MB2, or anti-DR7 activity. As shown in Fig. 5, the reactivity 
with anti-BR4X7 was mostly eliminated, whereas the reactivity of anti-MB2 antisera 240  GENETIC  CONTROL  OF  HUMAN  Ia  ANTIGENS 
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Fro.  4.  la  typing of 30  lymphoid cell  lines.  All  typings were  performed by  radioimmunoassay. 
Results are presented as described in the legend to Fig. 3. 
TABLE  IV 
Segregation of MB2 in Three Families Studied in the Eighth Histocompatibility Workshop 
8WFER01  haplotypes  8WFER09 haplotypes  8WTOS 18 haplotypes 
a:  A2,  B5,  C-,  DRw6  a:  A1,  B8,  C-,  DR3  a:  A2,  B7,  C-,  DRw6 
b:  A2,  B18,  C-,  DR5  b:  A26, Bw38, C-,  DRw6  b:  A-,  Bw50, Cw6, DR3 
c:  A2,  B5,  C-,  DR5  c:  A25, B5,  CW1,  DRw6  c:  Aw32, Bw60, Cw2, DR5 
d:  Aw33, Bw44, C-,DR7  d:  A26, Bw39, C-,  DR2  d:  A2,  B18,  C-,  DR5 
DC1  MB2  BR4X7  DC1  MB2  BR4X7  DC1  MB2  BR4X7 
Father  a/b  +  -  -  Father  a/b  +  +  -  Father  a/b  +  +  - 
Mother c/d  -  +  +  Mother c/d  +  -  -  Mother c/d  -  -  - 
Sib*  1  a/d  +  +  +  Sib  1  a/c  +  +  -  Sib  1  b/d  -  +  - 
2  a/d  +  +  +  2  a/c  +  +  -  2  a/c  +  -  - 
3  a/d  +  +  +  3  b/d  +  -  -  3  a/d  +  -  - 
4  a/d  +  +  +  4  b/c  +  -  -  4  a/d  +  -  - 
5  a/c  +  -  -  5  a/c  +  +  - 
6  b/d  -  +  + 
7  a/c  +  -  - 
8  b/d  -  +  + 
* Sibling. TANIGAKI, TOSI,  DUQUESNOY,  AND FERRARA 
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Fxc. 5.  Identification  of three  Ia  subsets  by sequential  binding assay.  125I-labeled LG-10  Ia 
preparation (420,000 cpm)  was treated with  serum  HON  (anti-BR4X7;  0.5 ~tl) and  tested  for 
binding activity with three groups of antisera; anti-BR4X7, anti-MB2, and anti-DR7. The labeled 
preparation (280,000 cpm) depleted of BR4X7 by this treatment was subsequently  treated either 
with Fe96/19, (anti-MB2; 50 #l) or with Fe53/23, (anti-DR7, BR4X7; 25/~1) and then assayed for 
binding activity with two groups of antisera;  anti-MB2  and anti-DR7.  The binding activity was 
assayed with 5 ~1 of each antiserum. Results are expressed as the percentage of the binding given by 
the ~sI-labeled LG-I0 preparation treated with normal serum under the same conditions and shown 
by a histogram. Three of the anti-DR7 antisera used (Fe27/26, Fe118/13 and Eckert) apparently 
possessed an anti-MB2 activity. It can be seen in a weak but significant reduction  (10-20%) of their 
binding with the LG-10 la preparation treated with HON and Fe96/19, and also in a weak but 
relatively high level (>20%) of their binding with the LG- 10 Ia preparation treated with HON and 
Fe53/23. 
as well as anti-DR7 antisera remained essentially unaffected, showing that DR7  and 
MB2  are carried by molecules different from  those carrying BR4X7.  The  LG-10 Ia 
preparation  absorbed with  the  HON  antiserum  was  subsequently  absorbed  either 
with  Fe96/19  (anti-MB2)  or with Fe53/23  (anti-DR7,  BR4X7)  and tested with the 
two  groups  of antisera corresponding to  these specificities. The  data obtained con- 
formed  to a  reciprocal nonabsorption  pattern,  showing that  Fe96/19  indeed shares 
the MB2 specificity with Duffy and Tellier and that the MB2 determinant is carried 
by Ia molecules different from those carrying the DR7 determinant. 
Microfingerprinting Patterns.  Three Ia subsets were isolated from the 125I-labeled LG- 
10  preparation  with  the corresponding antisera  and  separately analyzed.  Fe53/23, 
HON,  and Fe96/19  antisera were used  for the isolation of DR7,  BR4X7,  and MB2 
subsets, respectively. For the isolation of DR7  molecules, the LG-10 preparation was 
pre-absorbed with the HON  antiserum to remove BR4X7  molecules, because Fe53/ 
23 possessed anti-BR4X7 reactivity. Immune complexes formed with the three antisera 
were absorbed on protein A-coupled Sepharose, then the Ia subunits were separated 
by  SDS-polyacrylamide  gel  electrophoresis  and  subjected  to  microfingerprinting 
analysis after digestion with elastase. The patterns obtained for the three Ia subsets 
are shown  in  Fig.  6.  The  relevant  features  can  be summarized  as  follows:  (a)  The 
three subsets markedly differ from each other in the fi-chains. Only a group of four to 
five spots on the lower right (circled on Fig. 6 D)  is preserved. This group of peptides 
is present in all Ia fi-chains so far analyzed and may constitute an invariant marker 
of these  molecules.  The  comparison  between  DR7  and  BR4X7  reveals little or no 
difference in the a-chains. In both preparations a  group of intensely labeled spots is 
present on the bottom, corresponding to peptides of low chromatographic migration. 242  GENETIC  CONTROL  OF  HUMAN  la  ANTIGENS 
Fie.  6.  Peptide maps by microfingerprinting of the a- and fl-chains  of DR7, BR4X7, and MB2 
molecules isolated  from LG-10 cells. The isolation,  enzymatic digestion,  and peptide mapping of Ia 
subunits  were performed as described  in Materials and Methods.  Applied radioactivity was  10,000 
20,000 cpm and exposure  time was 72 h. The arrow (C) indicates  a peptide unique to the a-chains 
of MB2 and  DCI  (see Fig.  7A). The circle (D)  indicates  a  group of peptides common to the fl- 
chains  of DR7, BR4X7, and MB2 (see also Fig. 7 B). 
These  are  hydrophilic  peptides  that  may  possess  a  carbohydrate  moiety.  The  MB2 
ol-chains  possess  clearly distinctive  features.  First,  it  essentially  lacks  the  hydrophilic 
peptides.  Second,  the  other  spots  show  differences  in  position  and  intensity  as 
compared  with  BR4X7  a- and  DR7  a-chains.  Third,  it  has a  central  spot,  indicated 
by  the  arrow,  which  has  been  found  for  DC1  a-chains  as  shown  for  those  isolated 
from  Daudi  (DRw6,  DC1)  cells to  facilitate  a  direct  comparison  (Fig.  7).  This  spot 
has not been seen for other Ia o~-chains so far analyzed  (15). 
Discussion 
The  present  report  shows  that  three  antigenic  specificities  can  be  identified  in  Ia 
molecules from an HLA-homozygous  cell line. These three specificities, DR7, BR4X7, TANIGAKI, TOSI, DUQUESNOY, AND FERRARA  243 
FIG.  7.  Peptide maps by mierofingerprinting of the a- and ,8-chains of DC 1 molecules from Daudi 
cells. These patterns were presented to facilitate a direct comparison  of the peptide maps of MB2 
and DC I molecules. 
and MB2 are recognized by different alloantisera. They show HLA-linked segregation 
in  families  and  they  are  distributed  in  the  population  according to  different  but 
partially  overlapping  patterns.  Sequential-binding  analysis  and  peptide  mapping 
have shown that these three determinants are carried by distinct sets of Ia molecules; 
therefore, they must be controlled by different genes. 
This conclusion is based on the characterization of the molecular subset carrying 
the  BR4X7  determinant  and  of that  carrying the  MB2  determinant  and  on  the 
demonstration that these two subsets are distinct from the DR7 molecular subset and 
are also different from each other. The evidence concerning the molecular entity of 
each of BR4X7 and MB2 subsets will be considered separately. 
Most  data  exploring  the  relationship  of BR4X7  with  DR  have  been  reported 
previously  (5,  9).  The evidence that  BR4X7-carrying and  DR7-carrying molecules 
are  different  entities  is  based  on  the  outcome  of sequential-binding  experiments 
indicating that these molecules possess distinct alloantigenic determinants recognized 
by different alloantisera and that the two kinds of molecules can be separated by the 
use of these antisera. Thus, the molecular subset that carried the BR4X7 determinant 
existed  in  the  Ia preparation  purified  from a  DR3/DR7,  and  this  subset  was  not 
absorbed out by either anti-DR3 or anti-DR7 antisera. Conversely, the pretreatment 
with anti-BR4X7 did not affect the DR3 and DR7 components. The BR4X7 subset 
was  also  demonstrated  in  the  Ia preparation  from  a  DR2/DR4  cell  line.  Similar 
sequential binding experiments showed that it is carried by a third molecular subset 
distinct  from the  DR2  and  DR4 subsets.  Therefore, we concluded that  BR4X7  is 
controlled by a separate locus different from the HLA-DR locus. This conclusion was 
also confirmed here by sequential-binding analysis using an LG-10 Ia (DR7/DRT) 
preparation  (Figs.  1 and 5).  In fact, the absorption with HON serum  (anti-BR4X7) 
did  not  significantly affect the binding of several  different  anti-DR7  antisera.  The 
same experiment also showed that BR4X7 and MB2 determinants are on different 
molecules, because the absorption with serum HON left MB2 reactivity unaffected. 
This set of converging data, in agreement with those reported by others (10),  firmly 
characterizes  BR4X7 as  an  a[loantigenic determinant  controlled  by an  allele  of a 
separate locus in linkage disequilibrium with the DR4, DR7, and DRw9 alleles of the 
DR locus. In the present  work, additional information on BR4X7 was provided in 
respect to the structural features. It should be noted that a  proof for the presence of 
two different Ia subsets primarily depends upon the sequential-binding data, In this 244  GENETIC CONTROL OF HUMAN Ia ANTIGENS 
respect, the structural data are secondary: they have been used to reveal the structural 
relationship of Ia subsets and to define the allelic variants. 
Molecular  binding data  on  MB2  are  reported  here  for the  first  time.  The  data 
indicate that most individuals who type for DR3 or DR7 are also positive for MB2, 
conforming  to  the  association  pattern  of MB2  shown  by  the  cytotoxicity assay. 
Because DR3 and  DR7 were not completely included within MB2,  this association 
must  be  a  result  of a  strong  disequilibrium  of linked  gene  products.  After  the 
association of DC1 with DR1, DR2, and DRw6, and the association of BR4X7 with 
DR4, DR7, and DRw9, this is the third example of multiple linkage disequilibrium 
in the human Ia system. The degree of linkage disequilibrium is extremely high in the 
sense that MB2 is found to be invariably associated with either DR3 or DR7. Such an 
extreme  degree of linkage  disequilibrium  must  reflect  a  close relation  of the corre- 
sponding loci and, perhaps, a selective advantage of the observed haplotypic combi- 
nations in addition. 
It is certain that the MB2 specificity is controlled by a third Ia locus differing from 
the loci  that encode DR7 and BR4X7. Also, it is very likely that MB2 and DCI are 
allelic products of the same locus. The demonstration that  the frequencies of MB 1, 
equivalent to DC 1, and MB2 are in Hardy-Weinberg equilibrium supports the notion 
that DC1 and MB2 are allelic (1 i). Moreover, the present immunochemical analyses 
have provided data indicating structural  similarities  between  DC1  and  MB2 mole- 
cules.  First,  MB2  molecules differ markedly in  both  a-  and ~8-subunits  from either 
DR7 or BR4X7  molecules.  Likewise,  DC1  molecules have  been  shown to  differ in 
both subunits from Ia molecules carrying different DR specificities (6) and also from 
the  BR4X7 molecules)  Second, the  microfingerprinting patterns  of MB2  a-chains 
and DC1 a-chains show some common features  (Figs.  6C and  7A). They essentially 
lack labeled  glycopeptides and share an  invariant  spot  not possessed by the DR or 
BR4X7 a-chains so far analyzed. Third, neither DC1 nor MB2 molecules react with 
rabbit  anti-Ia a-subunit  antiserum  Ul15, which binds  DR and  BR4X7 molecules; 
indeed,  this  was  exploited  to  obtain  Ia  preparations  enriched  in  DC1  or  MB2 
molecules. 
The data presented show the presence of a minimum of three HLA-linked loci: DR 
locus,  a locus that encodes DC1 or MB2, and a locus that encodes BR4X7. To assess 
the real number of HLA genes involved and their correspondence with the Ia subunits, 
the problem of the localization of the serological markers at the subunit level must be 
considered. All available evidence indictes that DR determinants are located either 
predominantly or exclusively on  the /?-chain.  In fact,  when  dissociated  Ia subunits 
were analyzed for their  binding with  specific alloantisera,  it  was  invariably found 
that only the fl-subunits could react (3, 9,  15). Supporting evidence has been derived 
from structural  studies showing that  the a-chains of Ia molecules carrying different 
DR specificities are very similar,  whereas  the fl-chains are different  (26-28).  As for 
the BR4X7 determinant, anti-BR4X7 antisera were found to react only with isolated 
Ia fl-chains (9). This evidence is supported by the finding that BR4X7 fl-chains are 
different from DR7 fl-chains (Figs. 6 D and E), whereas their a-chains are very similar 
(Figs. 6A and B). Similar observations have been made for Ia preparations of different 
phenotype, i.e., DR3 and DR7 or DR2 and DR4, by the use of a different proteolytic 
enzyme, pepsin, in the microfingerprinting analysis. 1 Therefore we conclude that the 
loci controlling DR7 and  BR4X7/~-chains must be HLA-linked. As to the gene or TANIGAKI, TOSI, DUQUESNOY, AND FERRARA  245 
genes controlling the corresponding a-chains, it is possible that, in analogy with the 
mouse, they are also HLA-linked, but as long as their alloantigenic determinants are 
not detected this hypothesis cannot be easily tested in the human system. 
The situation concerning the DC 1 and MB2 determinants must be considered with 
more caution. Previously reported data showed that the isolated/~-chains, but not a- 
chains,  react with anti-DCl  antisera  (3).  However this lack of reactivity cannot be 
considered a proof, because the subunits were dissociated by a  denaturing procedure 
that may eliminate some determinants. The microfingerprinting patterns of MB2 and 
DC 1 molecules show clear differences in  the/3-subunits  (Figs.  6 F  and  7 B).  The a- 
subunits  show,  besides  the  similarities  discussed  above, clear  differences  in  several 
spots that are certainly more conspicuous than those observed between different DR 
molecules  (Figs.  6C  and  7A).  Therefore  the  possibility  that  for  DC1  and  MB2 
molecules the alloantigenic determinants may reside on both subunits should not be 
disregarded.  If this is the case, it will follow that  DC a-chains are controlled by an 
HLA-linked locus because the  DC  determinants  so  far defined,  wherever they are 
located, are clearly inherited as HLA markers. 
The data presented also confirm a unique feature in the human Ia system, i.e., the 
phenomenon of selective subunit association. In the mouse, At~ and Ep subunits are 
associated with different a  subunits  (29).  In man, the same can be said at least  for 
DR7 and BR4X7 molecules from one side and DC1 and MB2 molecules on the other 
side.  It  is  possible  that  DR7  a-  and  BR4X7  a-subunits  are  not  identical.  In  fact, 
Markert and Cresswell  (30) have reported the presence of three a-chains of different 
isoelectric  points  in  a  DR-homozygous cell  line.  Whatever  the  mechanism  is,  it  is 
possible that this selective subunit association, which depends on the linkage between 
loci for the two subunits, underlies some distinct functional property of the different 
Ia subsets. 
Summary 
Three distinct molecular subsets with different structures and alloantigenic deter- 
minants were identified in human Ia antigens from cells of an HLA-Dw7 homozygous 
cell line.  The subsets carried DR7 specificity, BR4X7 supertypic specificity and MB2 
supertypic specificity, respectively, and were immunospecifically separated by the use 
of operationally  monospecific alloantisera.  These  specificities  showed  HLA-linked 
segregation  in  families  and  they were  distributed  in  the  population  according to 
different but partially overlapping patterns.  On peptide mapping analysis, the three 
subsets showed marked differences in the/3-chains. The a-chains of DR7 and BR4X7 
subsets  were  very similar  to each other,  whereas  the  a-chains of MB2  subset  were 
distinctive  from  those of DR7  and  BR4XT.  These  data  indicate  the presence  of a 
minimum of three HLA-linked loci; DR locus, a  locus that encodes BR4X7, and a 
locus that encodes MB2, and substantiate the three-loci concept for the genetic control 
of human Ia antigens. 
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